UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
350 Hills Street, Suite 106, Richland, Washington 99354
(Address of Principal Executive Offices) (Zip Code)
(509) 375-1202
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, $0.001 par value |
ISR |
NYSE American |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On February 10, 2021, Isoray Medical, Inc. (“Medical”), a wholly owned subsidiary of Isoray, Inc., entered into Addendum No. 1 (the “Addendum”) to its supply contract with Joint Stock Company «Isotope», a Russian company (“JSC Isotope”), originally dated August 26, 2020, for the purchase of Cesium-131. The Addendum updates delivery locations under the supply contract.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
10.1 |
Addendum No. 1 to Supply Contract, dated February 10, 2021, by and between Isoray Medical, Inc. and Joint Stock Company. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 12, 2021
Isoray, Inc., a Delaware corporation
By: /s/ Lori A. Woods
Lori A. Woods, CEO
Exhibit 10.1
Addendum No. 1 to
840/08625142/31/83-20
Date of signature: 2021.02.10
THE SELLER
Isotope - Regional Alliance, Joint-Stock Company (Isotope JSC)
Pogodinskaya str., 22, Moscow, 119435, Russia.
Phone: +7(495) 981-96-16.
THE BUYER
The Company Isoray Medical Inc.
350 Hills Street, Suite 106
Richland, WA 99354-5411 USA
THE BUYER and THE SELLERS have mutually agreed about the following:
1. |
Airport of destination in deliveries of the Product under Contract might be Los Angeles, New York (USA). |
All other terms and conditions are in accordance with Contract 840/08625142/31/83-20 dd 20.08.2020, Appendices 1 and 2. The present Addendum is an integral part of the Contract and may be signed via facsimile or Email.
THE SELLER | THE BUYER | ||
/s/ Konstantin Ershov | /s/ Jennifer Streeter | ||
Konstantin Ershov | Jennifer Streeter | ||
Director of Sales Department | 10 Feb 2021 | ||
JSC Isotope | Isoray - COO |